Abstract
The Brazilian population, a product of extensive genetic admixture between Europeans, Africans, and Amerindians, exhibits high levels of genomic diversity with significant pharmacogenetic (PGx) implications. This study, conducted by the Brazilian Pharmacogenomics Network (Refargen), analyzed 1,034 individuals to assess the distribution of PGx polymorphisms. The findings reveal that self-reported color is an unreliable proxy for genetic diversity, as PGx variations follow a continuous gradient of ancestry rather than discrete racial categories.
Introduction: The Challenge of Admixture
Most pharmacogenomic knowledge is derived from relatively homogenous ethnic groups. However, Brazil’s history of intermingling between native Amerindians, Europeans, and sub-Saharan Africans creates a complex genetic landscape. Using discrete categories like "White" or "Black" to predict drug response is clinically problematic in such an admixed population. This research quantifies PGx diversity and evaluates whether self-reported color or geography can accurately predict clinically relevant genetic markers.
Methods and Study Population
Researchers utilized data from the Brazilian Pharmacogenomics Network (Refargen), genotyping 44 loci across 12 "Very Important Pharmacogenes" (VIP), including the CYP family, ABCB1, and VKORC1. The study cohort consisted of 1,034 healthy, unrelated adults from various regions of Brazil, categorized by the Brazilian Census as branco (White), pardo (Brown), or preto (Black).
The team utilized multinomial log-linear regression to associate genetic markers with ancestry and color, and Wright’s $F_{ST}$ statistics to measure genetic divergence between population strata.
Key Insights: Beyond the Label
The study highlights that ancestry in Brazil exists on a continuum. While average European ancestry is higher in self-identified "Whites," individual variation within groups is substantial. Self-reported "Color" fails to capture this genomic heterogeneity. For many genes, polymorphism frequency varies linearly with the percentage of ancestral roots, regardless of self-identification. This "smoothing" effect means that genetic divergence between "White" and "Black" Brazilians is lower than between ancestral reference populations (e.g., European vs. African).
Results: Quantifying Divergence
Significant differences in allele frequencies were found at 11 of the 44 loci across Color groups. While overall divergence was low, specific genes like CYP3A5 showed moderate divergence ($F_{ST} > 0.05$), indicating areas where standardized dosing is most likely to fail.
Regional history also plays a role; for instance, the Northeast shows a stronger African genetic signature due to historical migration patterns. The study concludes that extrapolating PGx data from foreign "pure" cohorts to Brazilians is scientifically unsound because of the underlying admixture present even in those who identify as White.
Conclusion and Future Directions
The intrinsic heterogeneity of the Brazilian population must be acknowledged in clinical trial design and drug regulation. Moving forward, the focus should shift from self-reported race to individual ancestry proportions and their impact on clinical outcomes. Regulatory agencies like ANVISA are encouraged to consider local admixed data rather than relying solely on foreign benchmarks.
Limitations: This study did not include the Center-West region or significant numbers of Asian-descendant and Amerindian groups, which remain areas for future research.
Summary updated